Skip to content

4521.T

KAKEN PHARMACEUTICAL CO.,LTD.

プライム · 医薬品 · 医薬品 · JP

JPY 3,800.00
+0.13%
Ask drillr

Year over year

Reported trailing growth

Revenue
-18.3%
EBITDA
—
EBIT
—
EPS
-84.7%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+12.3%
EBITDA
—
EPS
+7.5%

Three-year CAGR

Revenue
+1.7%
EBITDA
-41.1%
EBIT
—
Net income
-26.7%
EPS
-26.9%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026